Published in J Exp Med on November 01, 1992
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med (1994) 4.20
Human tumor antigens recognized by T lymphocytes. J Exp Med (1996) 3.63
A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med (1995) 2.88
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med (1996) 2.30
Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol (1995) 2.12
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest (2001) 2.11
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol (2001) 1.89
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res (2009) 1.71
Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci U S A (1994) 1.61
Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A (1994) 1.56
Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med (2001) 1.50
Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol (1999) 1.47
Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med (1997) 1.40
Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest (2004) 1.37
MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue. Br J Cancer (1998) 1.30
Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med (2001) 1.26
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med (1995) 1.24
Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci U S A (1995) 1.20
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med (2004) 1.17
Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest (1994) 1.16
Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines (2010) 1.15
A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med (1998) 1.15
Isolation and characterization of a MAGE gene family in the Xp21.3 region. Proc Natl Acad Sci U S A (1995) 1.13
Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS One (2010) 1.12
Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol (2011) 1.11
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med (1996) 1.09
Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. J Virol (2003) 1.09
Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol (2011) 1.08
Cancer vaccines. BMJ (2015) 1.07
Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J Exp Med (1994) 1.05
Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc Natl Acad Sci U S A (2000) 1.03
T-cell antigens in cancer. Proc Natl Acad Sci U S A (1994) 1.01
Expression of MAGE genes in human colorectal carcinoma. Ann Surg (1996) 0.98
Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. J Exp Med (1995) 0.97
Immunotherapy in gastric cancer. World J Gastroenterol (2014) 0.96
Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol (2000) 0.96
Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. Ann Surg Oncol (2008) 0.94
Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol Rev (2014) 0.93
Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J Virol (1995) 0.93
Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes. J Exp Med (1996) 0.93
Immunotherapy for myeloid leukemias: current status and future directions. Leukemia (2008) 0.93
GD2 oligosaccharide: target for cytotoxic T lymphocytes. J Exp Med (1995) 0.93
Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis (1997) 0.91
MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. Ther Adv Vaccines (2014) 0.91
Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89
A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics (1996) 0.89
Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects. World J Immunol (2014) 0.87
Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother (2014) 0.86
Urinary benzene biomarkers and DNA methylation in Bulgarian petrochemical workers: study findings and comparison of linear and beta regression models. PLoS One (2012) 0.86
Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci (2014) 0.85
MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge. Biomed Res Int (2012) 0.84
Effects of interferon alfa and gamma on human uveal melanoma cells in vitro. Br J Ophthalmol (1995) 0.84
Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation. Biol Blood Marrow Transplant (2014) 0.84
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
CT45A1 acts as a new proto-oncogene to trigger tumorigenesis and cancer metastasis. Cell Death Dis (2014) 0.82
Immunotherapy of melanoma. EJC Suppl (2013) 0.81
Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587. Clin Exp Immunol (2005) 0.80
Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in small-cell lung cancer. Br J Cancer (1996) 0.80
Enhancing the recognition of tumour associated antigens. Folia Biol (Praha) (1994) 0.80
Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer. Br J Cancer (1999) 0.79
Tumor antigens discovery: perspectives for cancer therapy. Mol Med (1997) 0.79
Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy. Clin Diagn Lab Immunol (2000) 0.79
Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. Adv Immunol (2012) 0.78
Orchestration of CD4 T cell epitope preferences after multipeptide immunization. J Immunol (2013) 0.78
Improved Transgenic Mouse Model for Studying HLA Class I Antigen Presentation. Sci Rep (2016) 0.76
SST-2 tumor inoculation is a useful model for studying the anti-tumor immune response in SHR rats. Environ Health Prev Med (2003) 0.76
State of the art in tumor antigen and biomarker discovery. Cancers (Basel) (2011) 0.75
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell (1986) 14.96
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (1991) 13.90
SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol (1988) 12.84
The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature (1987) 12.43
Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods (1989) 9.42
A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods (1986) 8.88
Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature (1990) 6.23
In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature (1989) 5.08
Construction of a fusion gene that confers resistance against hygromycin B to mammalian cells in culture. Exp Cell Res (1985) 4.42
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol (1989) 3.60
The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med (1991) 3.22
Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A (1991) 3.15
Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med (1990) 2.58
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer (1987) 2.50
Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics (1992) 2.45
Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proc Natl Acad Sci U S A (1988) 2.34
Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature (1992) 2.12
Clonal analysis of cytotoxic T cell response against human melanoma. J Exp Med (1983) 2.07
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med (1980) 1.91
Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer (1989) 1.80
Selection of highly transfectable variant from mouse mastocytoma P815. Somat Cell Mol Genet (1985) 1.76
Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur J Immunol (1991) 1.51
Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide. J Exp Med (1990) 1.41
Epitopic analysis of detergent-solubilized HLA molecules by solid-phase radioimmunoassay. J Immunol Methods (1982) 1.25
Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response. Evidence that two peptide residues are buried in the MHC molecule. J Immunol (1992) 1.24
Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay. Immunogenetics (1987) 1.19
The identification of tyrosine as a common key residue in unrelated H-2Kd restricted antigenic peptides. Int Immunol (1991) 1.16
Nucleotide sequence of an HLA-A1 gene. Nucleic Acids Res (1990) 0.97
Efficient expression of tum- antigen P91A by transfected subgenic fragments. Immunogenetics (1992) 0.89
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 5.03
A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol (1985) 4.71
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med (1994) 4.20
DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol (1999) 3.76
Analytical study of microsomes and isolated subcellular membranes from rat liver. I. Biochemical methods. J Cell Biol (1974) 3.69
Human tumor antigens recognized by T lymphocytes. J Exp Med (1996) 3.63
Inactivation of ribosomes in vitro by colicin E 3 . Proc Natl Acad Sci U S A (1971) 3.53
[Teratocarcinoma of the mouse: isolation, culture and properties of pluripotential cells]. Ann Microbiol (Paris) (1973) 3.46
The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med (1991) 3.22
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19
BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity (1995) 3.13
An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res (2001) 3.08
Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics (1994) 2.93
T cell defined tumor antigens. Curr Opin Immunol (1997) 2.90
A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med (1995) 2.88
Inactivation of ribosomes in vitro by colicin E 3 and its mechanism of action. Proc Natl Acad Sci U S A (1972) 2.88
Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat Immunol (2001) 2.83
Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity (1997) 2.71
The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A (1996) 2.63
Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer (1987) 2.50
Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics (1992) 2.45
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci U S A (1989) 2.40
Analytical study of microsomes and isolated subcellular membranes from rat liver. IV. Biochemical, physical, and morphological modifications of microsomal components induced by digitonin, EDTA, and pyrophosphate. J Cell Biol (1974) 2.36
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A (1995) 2.34
Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proc Natl Acad Sci U S A (1988) 2.34
Analytical study of microsomes and isolated subcellular membranes from rat liver. 3. Subfractionation of the microsomal fraction by isopycnic and differential centrifugation in density gradients. J Cell Biol (1974) 2.32
Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell (1989) 2.31
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med (1996) 2.30
cDNA cloning of murine interleukin-HP1: homology with human interleukin 6. Eur J Immunol (1988) 2.26
Electron microscope examination of subcellular fractions. 3. Quantitative analysis of the microsomal fraction isolated from rat liver. J Cell Biol (1971) 2.22
Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol (1998) 2.21
Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol (1994) 2.19
Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity (2000) 2.10
Analytical study of microsomes and isolated subcellular membranes from rat liver. II. Preparation and composition of the microsomal fraction. J Cell Biol (1974) 1.95
Purification and properties of colicin E3 immunity protein. J Biol Chem (1974) 1.92
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med (1980) 1.91
Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med (1983) 1.89
Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci U S A (1977) 1.85
T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions. A hypothesis. Immunogenetics (1989) 1.84
Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer (1992) 1.83
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol (1994) 1.83
Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer (1989) 1.80
LAGE-1, a new gene with tumor specificity. Int J Cancer (1998) 1.76
Selection of highly transfectable variant from mouse mastocytoma P815. Somat Cell Mol Genet (1985) 1.76
The association of cholesterol, 5'-nucleotidase, and alkaline phosphodiesterase I with a distinct group of microsomal particles. J Cell Biol (1969) 1.70
DNA restriction and modification systems in Salmonella. I. SA and SB, two Salmonella typhimurium systems determined by genes with a chromosomal location comparable to that of the Escherichia coli hsd genes. Mol Gen Genet (1974) 1.68
DNA restriction and modification systems in Salmonella. SQ, a new system derived by recombination between the SB system of Salmonella typhimurium and the SP system of Salmonella potsdam. J Gen Microbiol (1976) 1.68
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med (1999) 1.67
Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res (1998) 1.66
MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer (2001) 1.65
Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc Natl Acad Sci U S A (1978) 1.63
A mechanism for genetic recombination generating one parent and one recombinant. Proc Natl Acad Sci U S A (1969) 1.63
Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer (1994) 1.62
DNA restriction and modification systems in Salmonella. II. Genetic complementation between the K and B systems of Escherichia coli and the Salmonella typhimurium system SB, with the same chromosomal location. Mol Gen Genet (1974) 1.62
Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci U S A (1994) 1.61
CD8beta endows CD8 with efficient coreceptor function by coupling T cell receptor/CD3 to raft-associated CD8/p56(lck) complexes. J Exp Med (2001) 1.61
Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer (1992) 1.57